Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.

Leukemia & lymphoma·2025

Same author

Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2020

Same author

Transformation of marginal zone lymphoma (and association with other lymphomas).

Best practice & research. Clinical haematology·2017

Same author

Recent advances in the development of Aurora kinases inhibitors in hematological malignancies.

Therapeutic advances in hematology·2015

Same author

Treating Burkitt Lymphoma in Adults.

Current hematologic malignancy reports·2015

Same author

PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research·2014

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab in indolent lymphomas.

Tarek Sousou¹, Jonathan Friedberg

¹James P. Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA.

Seminars in Hematology

|March 31, 2010

Summary

This summary is machine-generated.

Rituximab, an anti-CD20 antibody, has improved overall survival for indolent non-Hodgkin lymphoma (NHL). Further research is needed to optimize rituximab maintenance therapy for NHL patients.

Related Experiment Videos

Last Updated: Jun 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Hematology
Oncology
Immunotherapy

Background:

Indolent non-Hodgkin lymphoma (NHL) is characterized by slow growth and initial treatment response, but often relapses.
Rituximab, an anti-CD20 antibody, has significantly impacted indolent NHL treatment.
Current treatment paradigms for indolent NHL involve chemotherapy and targeted therapies.

Purpose of the Study:

To review landmark clinical trials of rituximab in indolent NHL.
To summarize the efficacy of rituximab as a single agent and in combination chemotherapy.
To evaluate rituximab maintenance strategies and their impact on patient outcomes.

Main Methods:

Review of published clinical trials and data from the National Cancer Institute.
Analysis of data from studies investigating rituximab monotherapy and combination regimens.
Examination of rituximab maintenance dosing schedules and their associated outcomes.

Main Results:

Rituximab has demonstrated significant efficacy in treating indolent NHL.
Overall survival for indolent NHL patients has improved following the introduction of rituximab.
Rituximab maintenance therapy shows promising results in ongoing investigations.

Conclusions:

Rituximab has transformed the treatment landscape for indolent NHL.
Optimal rituximab dosing schedules and patient selection for maintenance therapy require further investigation.
Continued research is essential to maximize the benefits of prolonged rituximab treatment in indolent NHL.